Zhen Su, Chief Executive Officer and Member Board of Directors at Marengo Therapeutics, shared a post on LinkedIn:
“An unforgettable day for the cancer immunotherapy community at the New York Stock Exchange.
It was a privilege to convene the Society for Immunotherapy of Cancer (SITC) Biotech Strategic Meeting and join colleagues in ringing the NYSE Opening Bell – recognizing the remarkable progress of cancer immunotherapy and the community making it possible.
Throughout the day, leaders from biotechnology, academia, investment, and industry explored the forces shaping the next chapter of our field: commercializing immuno-oncology innovation, evolving capital markets and partnership models, building new companies, biotech liquidity and MandA, China’s role in global innovation, AI-assisted therapeutics, and the technologies poised to disrupt the future.
The discussions reinforced an important message: transformative advances rarely happen in isolation. They emerge when courageous science, thoughtful capital, strategic partnership, and a shared commitment to patients come together.”
Other articles featuring Zhen Su on OncoDaily.